Johnson & Johnson (J&J) announced results from the phase 3 investigational study of its targeted oral peptide icotrokinra for treating plaque psoriasis. Within six months of starting the treatment, the company reported that the majority of study subjects taking icotrokinra achieved clear or almost clear skin.
